NA
ITRM

Neuburgh Advisers’s Iterum Therapeutics ITRM Stock Holding History

Neuburgh Advisers’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$238K Sell
2,686
-111
-4% -$10.8K 0.01% 642
2019
Q2 		$289K Sell
2,797
-521
-16% -$57.9K 0.01% 597
2019
Q1 		$400K Sell
3,318
-794
-19% -$72.8K 0.01% 502
2018
Q4 		$309K Hold
4,112
– – 0.01% 529
2018
Q3 		$413K Sell
4,112
-20
-0.5% -$2.61K 0.01% 513
2018
Q2 		$675K Buy
+4,132
New +$746K 0.02% 357

Other funds holding ITRM

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Flinton Capital Management Philadelphia, Pennsylvania $3.22B AUM 4.75% 1-Year Est. Return
TAM
Tyers Asset Management Austin, Texas $3.02B AUM 5.29% 1-Year Est. Return

Neuburgh Advisers's ITRM Position: Q3 2019 in Review

Neuburgh Advisers reduced its Iterum Therapeutics (ITRM) stake by 4% in Q3 2019, selling an estimated $10.8K and leaving 2,686 shares worth $238K. The position accounts for 0.01% of the portfolio, ranked #642.

Neuburgh Advisers first reported a position in ITRM in Q2 2018 and has held it in 6 quarters since. The position peaked at $675K in Q2 2018. 19 funds tracked by Wall St. Rank hold ITRM as of Q3 2019.

  • Neuburgh Advisers held 2,686 shares of Iterum Therapeutics worth $238K as of Q3 2019.
  • Neuburgh Advisers sold 111 Iterum Therapeutics shares in Q3 2019, an estimated $10.8K.
  • Iterum Therapeutics made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #642 holding.
  • Neuburgh Advisers first reported a position in Iterum Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Neuburgh Advisers's Iterum Therapeutics position peaked at $675K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.